Fingolimod for the treatment of remitting multiple sclerosis: experience of the Moscow Multiple Sclerosis Center (MMSC)
https://doi.org/10.21518/2079-701X-2014-5-60-63
Abstract
13 patients from the Moscow Multiple Sclerosis Center with remitting MS and not responsive to treatment with 1st line DMD were given Fingolimod (Gilenya) starting from January 2012. After one year of therapy, the group demonstrated a significant decrease in the frequency of exacerbations from 2,54 ± 0,97 to 0,15 ± 0,38 (p ≤ 0,0001) per year, and showed no disability progression according to EDSS. Other results were good tolerability and safety of therapy, no clinically relevant deviations in hematological state, no ophthalmic complications. In view of the possible risk of transient bradycardia, before starting fingolimid therapy MS patients were examined, and their heart was monitored for 6 hours after they were given first dose. The monitoring registered a decrease in heart rate within permissible range (not requiring medical intervention) in 30.76% of cases at 34th hour, and by 6th hour the heart rate returned to the baseline value.
About the Authors
E. V. Popova
City Clinical Hospital No. 24 of the Moscow City Health Department; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
A. A. Yalymov
City Clinical Hospital No. 24 of the Moscow City Health Department; MSUMD named after A.I. Evdokimov
Russian Federation
Russian Federation
A. N. Boyko
City Clinical Hospital No. 24 of the Moscow City Health Department; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
M. V. Davydovskaya
City Clinical Hospital No. 24 of the Moscow City Health Department; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
E. V. Kolyak
City Clinical Hospital No. 24 of the Moscow City Health Department
Russian Federation
Russian Federation
O. V. Traktirskaya
City Clinical Hospital No. 24 of the Moscow City Health Department; Pirogov Russian National Research Medical University; MSUMD named after A.I. Evdokimov
Russian Federation
Russian Federation
N. V. Khachanova
City Clinical Hospital No. 24 of the Moscow City Health Department; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
S. G. Schur
City Clinical Hospital No. 24 of the Moscow City Health Department
Russian Federation
Russian Federation
References
1. Попова Н.Ф. План управления рисками при использовании рекомендации по терапии препаратом Гилениа (финголимод) у больных рассеянным склерозом. Журн неврол. и психиат. 2011 (2)2: 110-113.
2. Сидоренко Т.В., Хачаанова Н.В., Бойко А.Н. Разносторонняя поддержка и аргументированная мотивация пациентов с рассеянным склерозом - залог успеха длительной терапии. Журн неврол. и психиат. 2006, 3: 96-100.
3. Cohen JA, Barkhof., Comi G et al. Oral fingolimod or intramuscular interferon ffor relapsing multiple sclerosis. N Engl J Med. 2010, 326: 402-415.
4. Kappos L, Radue EM, O'Connor P et al. For the FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010, 326: 387-401.
5. Radue E et al. Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis. Arch Neurol., 2012.
6. Simon JH. Brain Atrophy in Multiple Sclerosis. Mult Scler, 2006, 12 (6): 679-687.
Review
For citations:
Popova EV, Yalymov AA, Boyko AN, Davydovskaya MV, Kolyak EV, Traktirskaya OV, Khachanova NV, Schur SG. Fingolimod for the treatment of remitting multiple sclerosis: experience of the Moscow Multiple Sclerosis Center (MMSC). Meditsinskiy sovet = Medical Council. 2014;(5):60-63. (In Russ.) https://doi.org/10.21518/2079-701X-2014-5-60-63
Views:
484
Email this article 